Search Results | Diabetes Care | American Diabetes Association

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study

José Ignacio Martínez-Montoro, María José Picón-César, Víctor José Simón-Frapolli, José Luis Pinzón-Martín, Jorge García-Alemán, María Durán-Martínez, Francisco J. Tinahones

Diabetes Care dc230083

DOI: https://doi.org/10.2337/dc23-0083

Published: 08 March 2023

View article

Journal Articles

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink

Diabetes Care 2023;46(3):602–607

DOI: https://doi.org/10.2337/dc22-1514

Published: 20 January 2023

View article

Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Rena Pollack, Itamar Raz, Stephen D. Wiviott, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Ofri Mosenzon, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Avivit Cahn

Diabetes Care 2023;46(1):156–164

DOI: https://doi.org/10.2337/dc22-1318

Published: 18 November 2022

View article

Journal Articles

Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial

Viktor Rotbain Curovic, Mie Klessen Eickhoff, Teemu Rönkkö, Marie Frimodt-Møller, Tine Willum Hansen, Harald Mischak, Peter Rossing, Tarunveer Singh Ahluwalia, Frederik Persson

Diabetes Care 2022;45(11):2662–2668

DOI: https://doi.org/10.2337/dc22-1157

Published: 23 August 2022

View article

Journal Articles

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Diabetes Care 2022;45(10):2350–2359

DOI: https://doi.org/10.2337/dc22-0382

Published: 23 August 2022

View article

Journal Articles

The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes

Roselle A. Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A. Margot Umpleby, Barbara A. Fielding, Melanie Davies, David L. Russell-Jones

Diabetes Care 2022;45(6):1408–1415

DOI: https://doi.org/10.2337/dc21-2043

Published: 21 March 2022

View article

Journal Articles

Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study

Haiyan Cheng, Zhou Zhang, Bing Zhang, Wen Zhang, Jin Wang, Wenyu Ni, Yingwen Miao, Jiani Liu, Yan Bi

Diabetes Care 2022;45(5):1201–1210

DOI: https://doi.org/10.2337/dc21-2064

Published: 09 March 2022

View article

Journal Articles

Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334–1343

Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Russell Esterline, Matthijs K.C. Hesselink, Joris Hoeks, Vera B. Schrauwen-Hinderling, Bas Havekes, Jan Oscarsson, Esther Phielix, Patrick Schrauwen

Diabetes Care 2022;45(5):1297

DOI: https://doi.org/10.2337/dc22-er05a

Published: 03 March 2022

View article

Journal Articles

Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose

Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, Olga Lavryneko, John Adams, Amalia Gastaldelli, Curtis Triplitt, Ralph A. DeFronzo, Eugenio Cersosimo

Diabetes Care 2022;45(6):1372–1380

DOI: https://doi.org/10.2337/dc21-1798

Published: 02 March 2022

View article

Journal Articles

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

Ana Palanca, Falco van Nes, Felipe Pardo, F. Javier Ampudia Blasco, Chantal Mathieu

Diabetes Care 2022;45(3):650–658

DOI: https://doi.org/10.2337/dc21-1584

Published: 21 January 2022

View article

Journal Articles

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Ahmed A. Kolkailah, Stephen D. Wiviott, Itamar Raz, Sabina A. Murphy, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, John P.H. Wilding, Ingrid Gause-Nilsson, Marc S. Sabatine, Darren K. McGuire

Diabetes Care 2022;45(2):e27–e29

DOI: https://doi.org/10.2337/dc21-1668

Published: 17 January 2022

View article

Journal Articles

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2022;45(4):938–946

DOI: https://doi.org/10.2337/dc21-1744

Published: 11 January 2022

View article

Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes Care 2021;44(8):1805–1815

DOI: https://doi.org/10.2337/dc21-0076

Published: 11 August 2021

View article

Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink

Diabetes Care 2021;44(8):1894–1897

DOI: https://doi.org/10.2337/dc21-0300

Published: 28 June 2021

View article

Journal Articles

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

Diabetes Care 2021;44(6):1334–1343

DOI: https://doi.org/10.2337/dc20-2887

Published: 15 April 2021

View article

Journal Articles

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Avivit Cahn, Itamar Raz, Lawrence A. Leiter, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

Diabetes Care 2021;44(5):1159–1167

DOI: https://doi.org/10.2337/dc20-2492

Published: 02 March 2021

View article

Journal Articles

Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones

Diabetes Care 2021;44(3):e61

DOI: https://doi.org/10.2337/dci20-0072

Published: 11 February 2021

View article

Journal Articles

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care 2021;44(3):e59–e60

DOI: https://doi.org/10.2337/dc20-2575

Published: 11 February 2021

View article

Journal Articles

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Diabetes Care 2021;44(2):586–594

DOI: https://doi.org/10.2337/dc20-1675

Published: 18 December 2020

View article

Journal Articles

Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition

Peter Wolf, Paul Fellinger, Lorenz Pfleger, Hannes Beiglböck, Patrik Krumpolec, Chiara Barbieri, Amalia Gastaldelli, Jürgen Harreiter, Matthäus Metz, Thomas Scherer, Maximilian Zeyda, Sabina Baumgartner-Parzer, Rodrig Marculescu, Siegfried Trattnig, Alexandra Kautzky-Willer, Martin Krššák, Michael Krebs

Diabetes Care 2021;44(2):541–548

DOI: https://doi.org/10.2337/dc20-1983

Published: 14 December 2020

View article

NARROW

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes

Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study

Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334–1343

Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only